{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T06:44:37Z","timestamp":1706769877876},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["11\/02 867"],"award-info":[{"award-number":["11\/02 867"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.trim.2015.09.002","type":"journal-article","created":{"date-parts":[[2015,9,24]],"date-time":"2015-09-24T15:38:22Z","timestamp":1443109102000},"page":"146-151","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Everolimus is safe within the first month after liver transplantation"],"prefix":"10.1016","volume":"33","author":[{"given":"Manuel","family":"Rodr\u00edguez-Per\u00e1lvarez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Indhira","family":"P\u00e9rez-Medrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Guerrero-Misas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Poyato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Barrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo","family":"Ferr\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan C.","family":"Pozo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"S\u00e1nchez-Fr\u00edas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rub\u00e9n","family":"Ciria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Brice\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 L.","family":"Montero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel De","family":"la Mata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.trim.2015.09.002_bb0005","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/ajt.12669","article-title":"Everolimus inhibits anti-HLA I antibody-mediated endothelial cell signaling, migration and proliferation more potently than sirolimus","volume":"14","author":"Jin","year":"2014","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2015.09.002_bb0010","doi-asserted-by":"crossref","unstructured":"Asrani SK, Wiesner RH, Trotter JF, Klintmalm G, Katz E, Maller E, et al. De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000\u20132003 phase II prospective randomized trial. Am. J. Transplant. 2014:14:356\u2013366.","DOI":"10.1111\/ajt.12543"},{"key":"10.1016\/j.trim.2015.09.002_bb0015","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/lt.23479","article-title":"Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the scientific registry of transplant recipients database","volume":"18","author":"Watt","year":"2012","journal-title":"Liver Transpl."},{"key":"10.1016\/j.trim.2015.09.002_bb0020","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jhep.2011.06.012","article-title":"The use of sirolimus should be restricted in liver transplantation","volume":"56","author":"Massoud","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.trim.2015.09.002_bb0025","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.trim.2015.09.002_bb0030","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1002\/lt.20707","article-title":"Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results","volume":"12","author":"Levy","year":"2006","journal-title":"Liver Transpl."},{"key":"10.1016\/j.trim.2015.09.002_bb0035","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1111\/j.1600-6143.2010.03128.x","article-title":"Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function","volume":"10","author":"Masetti","year":"2010","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2015.09.002_bb0040","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1111\/j.1600-6143.2012.04212.x","article-title":"Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial","volume":"12","author":"De Simone","year":"2012","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2015.09.002_bb0045","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1111\/ajt.12280","article-title":"Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study","volume":"13","author":"Saliba","year":"2013","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2015.09.002_bb0050","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1111\/j.1600-6143.2012.04049.x","article-title":"A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation-PROTECT","volume":"12","author":"Fischer","year":"2012","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2015.09.002_bb0055","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/S0168-8278(13)60182-8","article-title":"Everolimus-based immunosuppression in HCV positive de novo liver transplant recipients: 24-month results of a randomized controlled trial (abstract)","volume":"58","author":"Saliba","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.trim.2015.09.002_bb0060","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/ajt.12615","article-title":"Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation","volume":"14","author":"Sterneck","year":"2014","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2015.09.002_bb0065","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.jhep.2013.07.012","article-title":"Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma","volume":"59","author":"Rodriguez-Peralvarez","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.trim.2015.09.002_bb0070","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1111\/j.1600-6143.2012.04140.x","article-title":"Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis","volume":"12","author":"Rodriguez-Peralvarez","year":"2012","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2015.09.002_bb0075","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/tri.12372","article-title":"Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review","volume":"27","author":"Cholongitas","year":"2014","journal-title":"Transpl. Int."},{"key":"10.1016\/j.trim.2015.09.002_bb0080","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jhep.2012.04.015","article-title":"Evolution of indications and results of liver transplantation in Europe. A report from the European liver transplant registry (ELTR)","volume":"57","author":"Adam","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.trim.2015.09.002_bb0085","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1600-6143.2012.04306.x","article-title":"Reducing early exposure to calcineurin inhibitors: the key factor for a successful renal sparing strategy","volume":"13","author":"Rodriguez-Peralvarez","year":"2013","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2015.09.002_bb0090","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jhep.2012.09.019","article-title":"Early tacrolimus exposure after liver transplantation: relationship with moderate\/severe acute rejection and long-term outcome","volume":"58","author":"Rodriguez-Peralvarez","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.trim.2015.09.002_bb0095","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/lt.21827","article-title":"Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial","volume":"15","author":"De Simone","year":"2009","journal-title":"Liver Transpl."},{"key":"10.1016\/j.trim.2015.09.002_bb0100","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1432-2277.2008.00768.x","article-title":"Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function","volume":"22","author":"De Simone","year":"2009","journal-title":"Transpl. Int."},{"key":"10.1016\/j.trim.2015.09.002_bb0105","doi-asserted-by":"crossref","first-page":"337","DOI":"10.12659\/AOT.890673","article-title":"The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study","volume":"19","author":"Rostaing","year":"2014","journal-title":"Ann. Transplant."},{"key":"10.1016\/j.trim.2015.09.002_bb0110","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/01.TP.0000100685.70064.90","article-title":"Is there disparity between risk and incidence of cardiovascular disease after liver transplant?","volume":"77","author":"Neal","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2015.09.002_bb0115","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.intimp.2010.05.006","article-title":"Sirolimus has a potential to influent viral recurrence in HCV positive liver transplant candidates","volume":"10","author":"Wagner","year":"2010","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.trim.2015.09.002_bb0120","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1111\/j.1600-6143.2011.03767.x","article-title":"Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression","volume":"11","author":"McKenna","year":"2011","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2015.09.002_bb0125","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/tri.12100","article-title":"Induction immunosuppression in liver transplantation: a review","volume":"26","author":"Turner","year":"2013","journal-title":"Transpl. Int."},{"key":"10.1016\/j.trim.2015.09.002_bb0130","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/j.1600-6143.2011.03486.x","article-title":"Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study","volume":"11","author":"Boudjema","year":"2011","journal-title":"Am. J. Transplant."}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327415300198?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327415300198?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T02:58:27Z","timestamp":1537325907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327415300198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0966327415300198"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2015.09.002","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Everolimus is safe within the first month after liver transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2015.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}